Merck (MRK) EBT (2009 - 2026)

Merck (MRK) has reported EBT for 18 consecutive years, with -$683.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 113.66% year-over-year to -$683.0 million in Q2 2026; TTM through Jun 2026 was $5.9 billion, a 68.96% decrease from a year earlier, with the FY2025 full-year figure at $21.1 billion, up 5.67% from the prior year.
• EBT was -$683.0 million for Q2 2026 at Merck, up from -$3.5 billion in the prior quarter.
• Over five years, EBT peaked at $6.7 billion in Q3 2025 and troughed at -$5.3 billion in Q2 2023.
• A 5-year average of $3.1 billion and a median of $4.1 billion in 2024 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 218.9% in 2023 and soared 303.81% in 2024, its largest moves.
• Over 5 years, EBT stood at $3.5 billion in 2022, then sank by 158.24% to -$2.0 billion in 2023, then soared by 303.81% to $4.2 billion in 2024, then declined by 17.99% to $3.4 billion in 2025, then sank by 119.97% to -$683.0 million in 2026.
• The last three EBT figures came in at -$683.0 million (Q2 2026), -$3.5 billion (Q1 2026), and $3.4 billion (Q4 2025), per Business Quant data.